ArticleOncogene2026
LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of lymphomas, characterized by aggressive behavior and poor outcomes. Investigating the key regulatory long non-coding RNAs (lncRNAs) is helpful to refine current prognostic models and identify novel therapeutic targets in PTCL. Using clinical and transcriptomic data from 172 patients (training cohort) and 36 patients (validation cohort) with newly diagnosed nodal PTCL, this study identified LINC01727 (also known as IRENA) as an independent prognostic marker associated with poor outcomes. Functional assays demonstrated that IRENA significantly promoted tumor growth and inhibited T-lymphoma cell apoptosis, underscoring its oncogenic role in PTCL. Mechanistically, cytoplasmic IRENA acted as a scaffold, enhancing the interactions between Rho guanine nucleotide exchange factor 1 (ARHGEF1) and Formin-like protein 1 (FMNL1), as well as their binding to RHOA. Multi-omics analysis revealed that the scaffolding activity of IRENA established a positive feedback loop, thereby provoking RHOA/MAPK activation. In the murine cell-derived xenograft model, targeting IRENA with an antisense oligonucleotide (ASO) effectively suppressed T-lymphoma growth. This study identifies IRENA as an independent prognostic biomarker for nodal PTCL patients, revealing its role in the self-organizing activation of RHOA GTPase. Targeting the IRENA/RHOA/MAPK signaling axis by ASO may represent a potential therapeutic strategy for PTCL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.